Participants will undergo germline genomic sequencing as part of consenting to the WU-PE-CGS program.

Participants will be given the option to receive the results from the genomic sequencing. After they consent to the study, the types of results available to them will be explained by research staff. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information

Participants will receive a novel return of results report that is tailored to their choices.

Return of Genetic Results: Biomarker information from cancer cells

Return of Genetic Results: Inherited mutations related to cancer

Return of Genetic Results: Inherited mutations related to other medical issues

Graham Colditz, M.D., DrPH, MPH

Bettina Drake, Ph.D., MPH

Li Ding, Ph.D.

Bettina Drake, Ph.D.

Ryan Fields, M.D.

Yin Cao, ScD, MPH

Feng Chen, Ph.D.

Patricia Dickson, M.D.

Eric Duncavage, M.D.

Mark Fiala, MSW

Aimee James, Ph.D., MPH

Reyka Jayasinge, Ph.D.

Kian-Huat Lim, M.D., Ph.D.

Erin Linnenbringer, Ph.D., MS

Jessica Mozersky, Ph.D.

Mary Politi, Ph.D.

David Spencer, M.D., Ph.D.

Tunji Toriola, M.D., Ph.D., MPH

Ravi Vij, M.D., MBA

Mark Watson, M.D., Ph.D.

Fei Wan, Ph.D.

Mike Wendl, DSC, MS, PHS

Matthew Wyczalkowski, Ph.D.

Stephanie Solomon Cargill, Ph.D., MSPH

당뇨병성 망막증과 연령 관련 황반변성을 조기 발견하기 위해 AI 지원 진단 소프트웨어의 효과를 평가하는 연구입니다.

Intervention group (physicians assisted by AI): After the fundus photography is completed, the AI software (VeriSee AMD and VeriSee DR) will automatically retrieve and analyze the image data from Picture Archiving and Communication System (PACS) to generate the results. The research team will immediately provide the AI-generate results to physicians, enabling participants to receive their reports and results during the same visit. If any abnormalities are detected, the physicians will refer the participants for further ophthalmologic evaluation.

VeriSee DR is an AI-assisted diagnosis screening tool for diabetic retinopathy, the software received medical device license approval from the TFDA in 2020 (MOHW-MD-No.006966). VeriSee AMD is an AI-assisted diagnosis screening tool for age-related macular degeneration, the software also received medical device license approval from the TFDA in 2022 (MOHW-MD-No.007652).

VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration

Control group (physicians diagnosing without AI assistance): After the fundus photography is completed, participants will need to schedule a follow-up appointment with the attending physicians to receive their report and have preliminary assessment of the possibility of DR or AMD. If the physician detects any abnormalities, the physicians will refer the participants for further ophthalmologic evaluation.

The control group will undergo the fundus photography without AI-functionality, with reports interpreted solely by physicians. Participants must schedule a follow-up visit to receive their results.

Standard fundus photography with physician interpretation

Yi-Ting Hsieh, Medical Doctor

The participants in the intervention group will be added to a chat group in the Zalo app, created and managed by one investigator, which is named The Dementia Caregiver Support group. Weekly, the investigator will post one of the topics identified in Phase 1. Before posting the information, the investigator will ask the participants what topic they would like to read and discuss the week after by voting the answer. The posted information will be based on evidence-based resources and consulted by geriatricians, the neurologist, and the psychologist who specialize in dementia. Immediately after posting the topic, one investigator will call the participants to ensure they read and understand the post. The chat group monitor will also collect the questions or comments from the carers who are encouraged to share their feelings or experiences with relevant questions. Then the monitor will post the answers after consulting with the experts.

The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.

Information including knowledge and skills related to dementia patient care

The participants will receive usual care, introduced to the website Alzheimer.org to search for eligible information.

Caregivers will be introduce to the website www.alzheimer.org to search for eligible information

Usual care

University of Medicine and Pharmacy at Ho Chi Minh City

Participants in this arm will undergo the full diagnostic procedure under investigation. This includes :

* A blood sample collected for analysis by the investigational in vitro diagnostic device targeting biomarkers associated with bipolar disorder,
* Completion of validated psychiatric questionnaires, including the Mood Disorder Questionnaire (MDQ), used as clinical reference standards,
* Collection of sociodemographic and clinical data relevant to the psychiatric profile. This arm does not involve any therapeutic intervention. The objective is to evaluate the diagnostic concordance between the blood test and psychiatric screening tools.

Participants will undergo a venous blood draw for analysis by an investigational composite medical device designed to aid in the diagnosis of bipolar disorder. The device analyzes specific circulating biomarkers hypothesized to differ between patients with bipolar disorder and those with unipolar depression.

Venous blood sample for measuring blood biomarkers related to bipolar disorder

Participants will complete validated psychiatric screening tools used as reference standards to evaluate bipolar disorder, including the Mood Disorder Questionnaire (MDQ). These tools will be used to compare their diagnostic output with that of the investigational blood test.

유전자 검사 결과 반환: 암세포의 바이오마커 정보, 유전자 검사 결과 반환: 암과 관련된 유전적 돌연변이, 유전자 검사 결과 반환: 기타 의학적 문제와 관련된 유전적 돌연변이

당뇨병성 망막증 및 연령 관련 황반변성을 위한 VeriSee AI 지원 스크리닝 도구, 의사 해석이 포함된 표준 안저 사진 촬영

치매 환자 치료, 일반적인 치료와 관련된 지식 및 기술을 포함한 정보

양극성 장애와 관련된 혈액 바이오마커 측정을 위한 정맥혈 샘플, 표준화된 정신과적 평가 도구